This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Will GDP Revision Push Health Stocks Like Humana, Aetna Over a Cliff?

NEW YORK (TheStreet) -- Today's Q1 GDP report surprised many. The headline number -- overall U.S. GDP -- was chopped to a 2.9% annualized drop, down substantially from the previous reading of a 1.0% drop. That means that the economy is shrinking at a rate of nearly 3% a year.

By contrast, in the fourth quarter of 2013, GDP grew at an annualized 2.6%. This doesn't look good.

Millennials Inheritance Not Guaranteed: Boomer Parents Overspending

The Truth About Rental Cars and Insurance

Avoiding the 60-Day IRA Rollover Rule

According to Ian Shepherdson of Pantheon Economics, "Two-thirds of the revision is in consumption, cut to +1.0% from +3.1%. Almost all of this huge hit is in the health care services component, cut to -1.4% from +9.1%."

Estimates on health care spending seem to have been widely exaggerated if we believe in this huge revision downward in spending. Obamacare may have decreased health spending.

And with news like this, it is rather amazing that the health care sector is not selling off today.

Shares of Humana (HUM - Get Report), UnitedHealth (UNH - Get Report), Aetna (AET - Get Report), Cigna (CI) and WellPoint (WLP) are all positive on the day. These stocks are up substantially this year, prompting a couple of big questions for investors.

Could today's revision downward in health care spending be a sign that trouble is ahead for the sector? Or does today's action in the sector tell us that the GDP revision downward is merely an anomaly that will again be revised in the coming weeks?

It will likely be some time before we know the real truth about the revisions today. Still, investors should be mindful of the risk this report suggests, especially given the large price appreciation in the sector so far this year.

Let's look at what TheStreet Ratings has to say about Humana and Aetna stocks.

TheStreet Ratings team rates HUMANA INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

"We rate HUMANA INC (HUM) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

Highlights from the analysis by TheStreet Ratings Team goes as follows:
  • Compared to its closing price of one year ago, HUM's share price has jumped by 50.40%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, although almost any stock can fall in a broad market decline, HUM should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • Despite its growing revenue, the company underperformed as compared with the industry average of 16.8%. Since the same quarter one year prior, revenues rose by 11.7%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • HUM's debt-to-equity ratio is very low at 0.27 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.47, which illustrates the ability to avoid short-term cash problems.
  • Net operating cash flow has significantly increased by 62.86% to $671.00 million when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 37.82%.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AET $104.50 -1.50%
HUM $168.52 0.06%
UNH $114.07 0.78%
AAPL $118.13 -0.63%
FB $105.51 -0.22%


Chart of I:DJI
DOW 17,836.44 +24.25 0.14%
S&P 500 2,091.46 +2.32 0.11%
NASDAQ 5,121.3420 +18.5340 0.36%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs